Clinical trials: Apixaban, open to volunteers
Atrial Fibrillation Patients With Moderate or High Stroke Risk Who Had Undergone Catheter Ablation of Atrial Fibrillation
AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)
There has no evidence for the anticoagulation in patients who had undergone catheter ablation of atrial fibrillation, and has maintained sinus rhythm for more than 1 year.
- Trial name
- NCT04432220
- Testing
- Anticoagulation group(Apixaban group)
- Where
- South Korea
- Volunteers
- 840 people
- Sponsor
- Yonsei University
Venous Thromboembolism, Cancer
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).
- Conditions
- Venous Thromboembolism, Cancer, Upper Extremity Deep Vein Thrombosis, Catheter-Related Infections
- Trial name
- STREAM-Line (NCT06603870)
- Testing
- Anticoagulation Therapy
- Where
- 2 sites in Canada
- Volunteers
- 330 people
- Sponsor
- Ottawa Hospital Research Institute
Hemodialysis Access Failure, Kidney Disease, End-Stage
Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD)
This randomized, single-center, PROBE trial evaluates whether adding low-dose apixaban (2.5 mg orally every 12 hours) to standard intraluminal heparin lock prolongs primary functional patency of tunneled hemodialysis catheters…
- Conditions
- Hemodialysis Access Failure, Kidney Disease, End-Stage, Hemodialysis Catheter
- Trial name
- APICATH-HD (NCT07404345)
- Testing
- Apixaban, Heparin sodium lock solution
- Where
- Mexico
- Volunteers
- 54 people
- Sponsor
- Hospital Civil de Guadalajara
Atrial Fibrillation, Stroke
Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control
A prospective, non-blinded, multi-center study to assess the impact of early Catheter Ablation (CA) in patients with a new diagnosis of Atrial Fibrillation(AF) at the time of stroke. 100 patients will be enrolled.
- Trial name
- SAVE STROKE II (NCT06783868)
- Testing
- Catheter Ablation, Market-approved AVNB, OAC and AAD
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- Kansas City Heart Rhythm Research Foundation
Spinal Cord Injuries, Spinal Diseases
Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury
Currently, Enoxaparin is the usual prophylactic anticoagulant treatment at the acute and sub-acute phases of spinal cord injury (SCI).
- Trial name
- NCT05484557
- Testing
- Apixaban, Enoxaparin Sodium
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Loewenstein Hospital
Ischemic Stroke, Atrial Fibrillation
Single-stage Pulmonary Vein Isolation Combined With Percutaneous Left Atrial Appendage Occluder Implantation in Patients With Recent Onset Ischemic Stroke and Atrial Fibrillation
The project is a multicenter, open-label, randomized medical experiment, which was designed to evaluate the efficacy and safety of single-stage pulmonary vein isolation (PVI) and implantation of left atrial appendage occluder…
- Trial name
- PILOS-AF (NCT06212674)
- Testing
- PVI + LAAO, single stage, LAAO, NOAC
- Where
- 2 sites in Poland
- Volunteers
- 240 people
- Sponsor
- Medical University of Silesia
Cancer, VTE (Venous Thromboembolism)
DOAC - Dosing Options in AntiCoagulation Prophylaxis
Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death.
- Trial name
- DOAC (NCT07005024)
- Testing
- Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
- Where
- United States
- Volunteers
- 996 people
- Sponsor
- University of Vermont
Aortic Valve Disease
DIrect Oral Anticoagulation and Bioprothesis Aortic Valve
DIAMOND study is a national, multicentre, randomized, parallel-group, open label study in patients (aged ≥18 years) with aortic bioprosthesis (excluding TAVI) at least 7 days after cardiac surgery.
- Trial name
- DIAMOND (NCT05687448)
- Testing
- Apixaban 5 MG Oral Tablet, Aspirin 75 to 100mg once a day
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atrial Fibrillation, Left Atrial Appendage Absent
Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)
Left atrial appendage (LAA) closure has become a frequent addition to oral anticoagulation in patients with atrial fibrillation who undergo cardiac surgery.
- Conditions
- Atrial Fibrillation, Left Atrial Appendage Absent, Anticoagulant Adverse Reaction
- Trial name
- NCT06401616
- Testing
- OAC will be discontinued for the duration of the trial
- Where
- 6 sites in Denmark
- Volunteers
- 1,220 people
- Sponsor
- Odense University Hospital
Lymphoma, Leukemia
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Venous Thromboembolic Disease
- Trial name
- HEM-DOAC (NCT07270263)
- Testing
- Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Gdansk
Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB)
FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)
Background Non-vitamin K antagonist oral anticoagulants (NOACs) are recommended for stroke prevention in non-valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB), Gastrointestinal Hemorrhage (Clinically Important, Upper), Drug-Related Side Effects and Adverse Reactions
- Trial name
- FENOX (NCT07497893)
- Testing
- Fexuprazan, NOAC therapy
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Atrial Fibrillation, Coronary Artery Disease
Antithrombotic Strategy for AF Patients With High Risk CAD
Anticoagulation therapy is recommended for patients with atrial fibrillation (AF) in order to prevent ischemic stroke and systemic embolism.
- Trial name
- ADAPT AFFIRM (NCT06866665)
- Testing
- Anticoagulation Monotherapy, Combination therapy
- Volunteers
- 1,400 people
- Sponsor
- Yonsei University
Atrial Fibrillation (AF)
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban.
- Trial name
- ROXI-EVEREST (NCT07626411)
- Testing
- REGN7508, Apixaban
- Where
- 66 sites in United States, Canada and 1 more
- Volunteers
- 15,364 people
- Sponsor
- Regeneron Pharmaceuticals
Atrial Fibrillation on Apixaban Treatment
Application-Delivered Patient Education in Enhancing the Usage of Apixaban in Patients With Atrial Fibrillation
"AF is the most common arrhythmia, with an overall prevalence of approximately 2%. It is particularly prevalent in individuals over 60 years old, affecting about 5% of this population.
- Trial name
- NCT06869083
- Testing
- AF application enhancing AF education and drug adhrence, AF application without enhancing AF education and drug adhrence
- Where
- South Korea
- Volunteers
- 5,200 people
- Sponsor
- Yonsei University
Chronic Kidney Diseases, Atrial Fibrillation
Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
Objective: To study the efficacy and safety of apixaban as stroke prophylaxis in patients with chronic kidney disease (CKD) stage 5 and atrial fibrillation (AF) with or without dialysis treatment.
- Conditions
- Chronic Kidney Diseases, Atrial Fibrillation, Stroke, Intracerebral Hemorrhage
- Trial name
- SACK (NCT05679024)
- Testing
- Apixaban 2.5 milligram Oral Tablet
- Where
- 34 sites in Finland, Iceland and 2 more
- Volunteers
- 1,400 people
- Sponsor
- Region Stockholm
Non Valvular Atrial Fibrillation
Apixaban Versus Rivaroxaban in Non Valvular Atrial Fibrillation
The investigators will first measure the maximum concentration (after 2 hours of intake) and the residual concentration (just before the next intake) after at least 15 consecutive days of treatment.
- Trial name
- APIXA-Xa (NCT06862726)
- Testing
- Anti Xa dosage, Dosage of PT-INR
- Where
- Tunisia
- Volunteers
- 120 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Stroke, Atrial Fibrillation
The Incidence of New-brain Lesions on Brain MRI and Safety Between Edoxaban and Apixaban in Patients with Stroke and Nonvalvular Atrial Fibrillation
This study aims to determine whether there is a difference in brain lesion occurrence and safety when brain MRI is followed up between edoxaban and apixaban in stroke patients with nonvalvular atrial fibrillation through…
- Trial name
- APIXABAN (NCT06864052)
- Testing
- Administration of Apixaban, Administration of Edoxaban
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Ewha Womans University Seoul Hospital
Non-valvular Atrial Fibrillation (AF)
Vortosiran in Atrial Fibrillation
This is a randomised, actively controlled Phase IIb trial to evaluate the safety and pharmacodynamics (PD) of two blinded doses of subcutaneously administered vortosiran and open-label apixaban in patients with AF.
- Trial name
- NCT07870889
- Testing
- Vortosiran, Apixaban
- Where
- 15 sites in Denmark, Norway and 2 more
- Volunteers
- 150 people
- Sponsor
- Ribocure Pharmaceuticals AB
Obesity, Morbid
Bariatric Surgery and Pharmacokinetics of Apixaban
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines.
- Trial name
- NCT03448783
- Testing
- Apixaban
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Norwegian University of Science and Technology
Coagulation
Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™
The Perosphere ClotChek™ system consists of a hand-held, battery-operated blood coagulation instrument and disposable test cuvettes for use at the point-of-care (POC).
- Trial name
- NCT07012291
- Testing
- Whole Blood Clotting Time
- Where
- 4 sites in United States
- Volunteers
- 150 people
- Sponsor
- Perosphere Technologies Inc.